{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:19:11Z","timestamp":1790943551042,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006334","name":"Uniwersytet Jana Kochanowskiego w Kielcach","doi-asserted-by":"publisher","award":["SUPB.RN.23.014"],"award-info":[{"award-number":["SUPB.RN.23.014"]}],"id":[{"id":"10.13039\/501100006334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Polish Ministry of Science and Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e31189","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:55:49Z","timestamp":1715601349000},"page":"e31189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Macroenzymes as a reason for aminotransferases flare in cystic fibrosis patients on CFTR modulators therapy \u2013 Report of three cases"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4533-4699","authenticated-orcid":false,"given":"Marek","family":"Woynarowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-1717","authenticated-orcid":false,"given":"Ewa","family":"Sapiejka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8660-084X","authenticated-orcid":false,"given":"Maria","family":"J\u00f3\u017awiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Milczewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7297-5091","authenticated-orcid":false,"given":"Katarzyna","family":"Zybert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Krusi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Siwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-8894","authenticated-orcid":false,"given":"Aldona","family":"Wierzbicka-Ruci\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e31189_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic fibrosis foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.heliyon.2024.e31189_bib2","unstructured":"Kaftrio (iwacaftor, tezacaftor, elexsacaftor) Summary of Product Characteristics Updated 21-Apr-2023. Vertex Pharmaceuticals (Europe) Limited https:\/\/www.medicines.org.uk\/emc\/product\/13216\/smpc."},{"key":"10.1016\/j.heliyon.2024.e31189_bib3","article-title":"Acute liver failure in a patient with cystic fibrosis taking triple combination modulator","author":"Sharma","year":"2021","journal-title":"ATS Conference 2021 American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e31189_bib4","article-title":"Hope in every breath: navigating the therapeutic landscape of cystic fibrosis","volume":"15","author":"Sreenivasulu","year":"2023","journal-title":"Cereus"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e31189_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/antibiotics11111637","article-title":"Longitudinal study of therapeutic adherence in a cystic fibrosis unit: identifying potential factors associated with medication possession ratio","volume":"11","author":"Gir\u00f3n","year":"2022","journal-title":"Antibiotics"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e31189_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jcf.2023.01.007","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on liver tests at a large single adult cystic fibrosis centre","volume":"22","author":"Tewkesbury","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e31189_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.07.002","article-title":"The natural history of cystic fibrosis liver disease a prospective cohort study","author":"Rowland","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e31189_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2022.10.002","article-title":"Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis","volume":"22","author":"Southern","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e31189_bib9","unstructured":"B-112, Polish Ministry of Health and National Health Fund - therapeutic programm for patients with cystic fibrosis. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/www.gov.pl\/attachment\/7ad3c2d8-ed7c-43fe-8517-cbbd5b006fc4&ved=2ahUKEwjki9fT6JyFAxXAExAIHcQNBtUQFnoECB0QAQ&usg=AOvVaw0GmukS3DRcbSZbpnGVy7ug."},{"key":"10.1016\/j.heliyon.2024.e31189_bib10","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e31189_bib11","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1258\/000456303322326425","article-title":"Macroenzyme detection by polyethylene glycol precipitation","volume":"40","author":"Davidson","year":"2003","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.heliyon.2024.e31189_bib12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e31189_bib13","article-title":"Delayed hepatic necrosis in a cystic fibrosis patient taking Elexacaftor\/Tezacaftor\/Ivacaftor (Kaftrio)","volume":"34","author":"Salehi","year":"2021","journal-title":"Respir Med Case Rep"},{"key":"10.1016\/j.heliyon.2024.e31189_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","article-title":"Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR","volume":"21","author":"Drummond","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e31189_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000010","article-title":"Effects of CFTR modulators on serum biomarkers of liver fibrosis in children with cystic fibrosis","volume":"7","author":"Levitte","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.heliyon.2024.e31189_bib16","first-page":"411","article-title":"Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis World","volume":"14","author":"Ramsey","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e31189_bib17","first-page":"65","article-title":"Macro enzymes: prevalence, composition, detection and clinical relevance","volume":"28","author":"Sturk","year":"1990","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.heliyon.2024.e31189_bib18","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0016-5085(82)80331-4","article-title":"A rapid and simple assay to determine if macroamylase is the cause of hyperamylasemia","volume":"83","author":"Levitt","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2024.e31189_bib19","article-title":"Detection of macroenzymes: establishing upper reference limits for eight enzymes after polyethylene glycol precipitation","volume":"33","author":"Dedeene","year":"2023","journal-title":"Biochem. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e31189_bib20","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jpeds.2008.11.010","article-title":"Prevalence and long-term course of macro-aspartate aminotransferase in children","volume":"154","author":"Caropreso","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.heliyon.2024.e31189_bib21","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.12998\/wjcc.v7.i24.4414","article-title":"Isolated elevated aspartate aminotransferase in an asymptomatic woman due to macro-aspartate aminotransferase: a case report","volume":"7","author":"Zhan","year":"2019","journal-title":"WJCC"},{"key":"10.1016\/j.heliyon.2024.e31189_bib22","article-title":"A case of macroenzyme aspartate aminotransferase mimicking hepatic injury","volume":"13","author":"Schimming","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e31189_bib23","first-page":"280","volume":"vol. 32","author":"Simac","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e31189_bib24","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2017.07.003","article-title":"A heterozygous mutation in GOT1 is associated with familial macro-aspartate aminotransferase","volume":"67","author":"Kulecka","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2024.e31189_bib25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.bbapap.2014.10.015","article-title":"Laboratory and clinical features of abnormal macroenzymes found in human sera","volume":"1854","author":"Moriyama","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e31189_bib26","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e31189_bib27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5114\/ceh.2023.132264","article-title":"Increased aminotransferases do not necessarily mean hepatotoxicity of CFTR modulator therapy","volume":"9","author":"Woynarowski","year":"2023","journal-title":"Clin. Exp. Hepatol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024072207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024072207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:48:57Z","timestamp":1790239737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024072207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024072207"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31189","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macroenzymes as a reason for aminotransferases flare in cystic fibrosis patients on CFTR modulators therapy \u2013 Report of three cases","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e31189"}}